Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

An ethical approach for clinical trials during the COVID-19 pandemic

John Paul Mikhaiel, MD
Conditions
April 5, 2020
Share
Tweet
Share

As researchers and physicians race to investigate innovative therapeutics against the novel SARS-CoV-2 virus, unanswered questions remain regarding the ethics and design of clinical trials. Namely, what is the most ethically and scientifically rigorous approach to test unproven novel or repurposed therapeutic agents during a major public health emergency? Canonically, randomized controlled trials (RCTs) have represented the gold standard for evidence-based medicine. In this approach, the efficacy of an intervention is tested against a control intervention, generally the standard of care, with random assignment of patients to the two groups to avoid bias. While this framework, on its surface, seems most epistemically pure, it is important to recognize these trials will be taking place in the background of a catastrophic public health situation. As such, we need to balance individual and communal interests.

Many therapies, including remdesivir, chloroquine, hydroxychloroquine, azithromycin, and lopinavir-ritonavir, to name a few, have been proposed as potential therapies against COVID-19 based on in vitro and in silico models. While the conception of these drugs is based on medical theory, to create efficacious treatments, such medical theory must be married to empirical evidence, generated from observations and data. Due to their rigor, RCTs are unparalleled in combining medical and statistical theory to create progress in medicine.

By comparing groups that receive intervention to those in a control group, scientists are able to measure the effectiveness of that intervention on a pre-specified endpoint. Clinically robust endpoints for a COVID-19 trial include patient mortality and/or need for mechanical ventilation with ICU-level care. The need for a control group and randomization is imperative for minimizing bias and measuring efficacy. The randomization in these trials is ethical in those affected by COVID-19, as there is clinical equipoise between the treatments and standard of care, i.e., there is genuine uncertainty regarding the best therapy.

RCTs will be critical in finding a potential cure for COVID-19 and serve a broad communal interest. They must serve as the backbone of evidence for our treatment, as there is not yet a safe, proven treatment for COVID-19. While much promise has been touted regarding chloroquine, an anti-malarial drug, the evidence remains uncertain on its true efficacy. Examples abound of anecdotal evidence not panning out. For instance, in the 1970s, laetrile, a compound found in apricot pits, was touted for its anticancer benefits based on a case series. By 1978, more than 70,000 individuals in the U.S. were treated with it, only for a later retrospective analysis to find there was no definitive evidence of anticancer activity. With respect to COVID-19, poorly designed, and futile trials come with the opportunity cost of wasted data generation and at the expense of more credible interventions.

During the current pandemic, however, it is important to recognize that clinical trials are embedded in a complex web of social and economic factors. Not every patient will be able to enroll in a clinical trial, and for those that are enrolled, motives may not be purely altruistic, as there is past evidence to suggest participants in trials may be seeking some clinical benefit. The FDA’s recent guidelines for adaptive trials is vital in this regard. Adaptive methods vary, but the defining feature is that trial results from early participants can be used to adapt the treatment for later participants. These trials are attractive in emergency situations, as they are flexible with the main aim of minimizing harm to study participants, reducing the risks of research, and maximizing the benefits. Gilead Sciences, the company behind remdesivir, is currently using an adaptive trial design, which may produce results as soon as mid-April.

Finally, as in debates that surrounded early HIV trials, there is uncertainty regarding “compassionate” use of trial drugs and repurposed drugs that do not yet demonstrate efficacy. Agents used “compassionately” typically have evidence of safety, but there is no obligation for the data to contribute to evaluating the effectiveness of the drug. Some physicians believe that compassionate use drugs or repurposed drugs taken outside of a clinical trial interferes with research conduct and is a wasted opportunity to contribute to our collective knowledge. Such an approach discounts individual values, and the fear and anxiety that accompany a pandemic.

For instance, certain hospitals are using chloroquine and hydroxychloroquine off-label for ICU admissions of patients with COVID-19. To suggest patients and physicians should not attempt such therapies following a shared decision-making approach, is discordant with the AMA’s Principles of Medical Ethics, in which “a physician shall, while caring for a patient, regard responsibility to the patient as paramount.” The physician must assess each individual uniquely and, in certain circumstances, may deem the natural course of the SARS-CoV-2 virus is riskier than the intervention itself, especially in cases where the drugs have a long history of safety. The point is that without proven treatment options, therapeutic choices must be made on the basis of the patient-physician relationship until RCTs provide evidence one way or the other.

During the Ebola virus disease outbreak, the WHO issued guidelines for Monitored Emergency Use of Unregistered Interventions (MEURI), for diseases in which: 1) no proven effective treatments exist; 2) it is not possible to initiate clinical studies immediately; 3) there is informed consent; 4) and there is a positive risk-benefit analysis. This may be an effective framework to use in creating systematic documentation of clinical outcomes for the many drugs that may be repurposed in combating COVID-19. This method should not be used to circumvent clinical trials, but rather as another source to provide scientific information given the extreme circumstances.

The adaptive clinical trials being carried out will provide the best evidence for efficacious medications and appropriately balance communal with individual interests. Those in life-threatening situations that do not have access to a clinical trial may benefit from repurposed therapeutics, but should follow the WHO guidelines laid out for MEURI, given there is an adequate supply of those therapeutics. Such an approach navigates the tension between both individual and communal interests as well as the epistemic and ethical obligations of clinical trials.

John Paul Mikhaiel is a medical student. 

Image credit: Shutterstock.com

Prev

COVID-19 is a different world for our most vulnerable citizens

April 5, 2020 Kevin 0
…
Next

The oath we took does not include compromising our own safety

April 5, 2020 Kevin 2
…

Tagged as: COVID, Infectious Disease

Post navigation

< Previous Post
COVID-19 is a different world for our most vulnerable citizens
Next Post >
The oath we took does not include compromising our own safety

ADVERTISEMENT

More by John Paul Mikhaiel, MD

  • Uncovering the truth about racial health inequities in America: a book review

    John Paul Mikhaiel, MD
  • A medical student reviews Eric Topol’s Deep Medicine

    John Paul Mikhaiel, MD

Related Posts

  • The social determinants of health during the COVID-19 pandemic

    Heather Thompson Buum, MD
  • Growing pains: clinical training during COVID-19

    Kevin Jiang
  • Malpractice claims from the COVID-19 pandemic: more questions than answers

    Robert E. White, Jr. & The Doctors Company
  • Medical education in the COVID-19 pandemic can’t be ignored

    Casey Hribar and Carolyn S. Quinsey, MD
  • The uncertainty of an international medical graduate during the COVID-19 pandemic

    Juan J. Delgado-Hurtado, MD, MPH
  • The COVID-19 pandemic is a catalyst for reimagining future health care delivery

    Imelda Dacones, MD

More in Conditions

  • The truth about sun exposure: What dermatologists want you to know

    Shafat Hassan, MD, PhD, MPH
  • How a South Asian nurse challenged stereotypes in health care

    Viksit Bali, RN
  • Could ECMO change where we die and how our organs are donated?

    Deepak Gupta, MD
  • From Civil War tales to iPhones: a family history in contrast

    Richard A. Lawhern, PhD
  • The hidden dangers of over-the-counter weight-loss supplements

    STRIPED, Harvard T.H. Chan School of Public Health
  • How denial of hypertension endangers lives and what doctors can do

    Dr. Aminat O. Akintola
  • Most Popular

  • Past Week

    • How a doctor defied a hurricane to save a life

      Dharam Persaud-Sharma, MD, PhD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • Guilty until proven innocent? My experience with a state medical board.

      Jeffrey Hatef, Jr., MD | Physician
    • Why physician strikes are a form of hospice

      Patrick Hudson, MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
    • Federal shakeup of vaccine policy and the battle for public trust [PODCAST]

      American College of Physicians & The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Federal shakeup of vaccine policy and the battle for public trust [PODCAST]

      American College of Physicians & The Podcast by KevinMD | Podcast
    • Why clinicians must lead health care tech innovation

      Kimberly Smith, RN | Tech
    • The truth about sun exposure: What dermatologists want you to know

      Shafat Hassan, MD, PhD, MPH | Conditions
    • Learning medicine in the age of AI: Why future doctors need digital fluency

      Kelly D. França | Education
    • How a South Asian nurse challenged stereotypes in health care

      Viksit Bali, RN | Conditions
    • Doctors reclaiming their humanity in a broken system [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • How a doctor defied a hurricane to save a life

      Dharam Persaud-Sharma, MD, PhD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • Guilty until proven innocent? My experience with a state medical board.

      Jeffrey Hatef, Jr., MD | Physician
    • Why physician strikes are a form of hospice

      Patrick Hudson, MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
    • Federal shakeup of vaccine policy and the battle for public trust [PODCAST]

      American College of Physicians & The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Federal shakeup of vaccine policy and the battle for public trust [PODCAST]

      American College of Physicians & The Podcast by KevinMD | Podcast
    • Why clinicians must lead health care tech innovation

      Kimberly Smith, RN | Tech
    • The truth about sun exposure: What dermatologists want you to know

      Shafat Hassan, MD, PhD, MPH | Conditions
    • Learning medicine in the age of AI: Why future doctors need digital fluency

      Kelly D. França | Education
    • How a South Asian nurse challenged stereotypes in health care

      Viksit Bali, RN | Conditions
    • Doctors reclaiming their humanity in a broken system [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...